09:05 , Jul 16, 2019 |  BC Extra  |  Financial News

As it preps Phase III kidney trial on its own, AM-Pharma raises €116M series C

After Pfizer declined to exercise its option to acquire AM-Pharma, the Dutch biotech has turned to European venture investors for a €116 million ($131 million) series C round to fund a Phase III study of...
23:36 , Jul 15, 2019 |  BC Extra  |  Company News

Via Mavupharma takeout, AbbVie gets first-in-class STING target

The acquisition of Mavupharma gives AbbVie a first-in-class indirect STING booster close to the clinic that inhibits a target unexploited by other companies in oncology. James Topper of Frazier Healthcare Partners, which led three-year-old Mavupharma...
21:28 , Jun 25, 2019 |  BC Extra  |  Company News

WuXi AppTec raising U.S. profile to counter political attacks

WuXi AppTec plans to raise its profile in the U.S. in the hope that a better understanding of its activities will de-escalate political attacks on the company, co-CEO Edward Hu told BioCentury. While restrictions on...
00:43 , Jun 22, 2019 |  BC Extra  |  Financial News

WuXi stocks tumble as Rubio continues to press China agenda

WuXi Biologics and WuXi AppTec ended down about 6% in Hong Kong on Friday, losing a combined $765 million in market cap, as Sen. Marco Rubio (R-Fla.) continued to ratchet up pressure on China's life...
11:31 , Jun 10, 2019 |  BioCentury  |  Finance

$80M series B backs Oncologie's biomarkers, which could give new life to old therapies

Oncologie's strategy of pairing in-licensed, later-stage compounds with biomarkers led Nan Fung Life Sciences and Pivotal bioVenture Partners China to return to invest in the cancer company's tranched $80 million series B. The funds are...
04:00 , Jun 5, 2019 |  BioCentury  |  Finance

EpimAb raises $74M series B round to accelerate bispecific immuno-oncology pipeline expansion

With proof in hand that EpimAb can quickly move bispecific mAbs from concept to the clinic, the Shanghai company intends to use its $74 million series B round to rapidly expand its pipeline of bispecific...
00:29 , May 25, 2019 |  BC Extra  |  Financial News

New IPO filings include BridgeBio, Dermavant, Prevail, Atreca, Akero

In a week in which two biotechs went public and a third opted for a billion-dollar takeout instead of an IPO, five companies filed on Friday to list on NASDAQ in IPOs that could raise...
22:28 , May 6, 2019 |  BC Extra  |  Company News

Management tracks: Batu, Halozyme, FOG

Immunotherapy company Batu Biologics Inc. , (San Diego, Calif.) said founder Thomas Ichim has become president and CEO. Ichim, also a director, was previously Batu's CSO. He succeeds founder Samuel Wagner, who stepped down and...
00:01 , Apr 30, 2019 |  BioCentury  |  Finance

Why liver disease newco Alentis is aiming for one of largest Swiss A rounds

Liver disease newco Alentis Therapeutics is starting off small with the first close of its series A round, but the additional capital it expects to raise over the next six months could give it the...
14:31 , Apr 26, 2019 |  BC Extra  |  Financial News

Schizophrenia therapy developer Karuna among four biotechs to file for IPOs

Weeks after completing its $80 million series B round, antipsychotic therapy developer Karuna said it has filed confidential documentation with the SEC for a planned IPO. The company was one of four to unveil plans...